Inflammation is a predictor of cardiovascular disease (CVD). Thus, inflammatory bowel diseases (IBD) may be associated with CVD. We assessed carotid intima-media thickness (cIMT; an indicator of CVD risk) in 42 patients with IBD, free of CVD or diabetes; 26 with Crohn's disease (CD) and 16 with ulcerative colitis (UC). The cIMT was significantly greater in patients with IBD compared to 42 healthy controls (0.62 ± 0.08 vs 0.52 ± 0.06 mm; P < .0005). The cIMT did not differ between patients with CD and UC or between the different disease activity and treatment groups. Factors associated with cIMT were age, body mass index, and IBD, with the latter making a greater contribution. The IBD is a predictor of cIMT, even when other CVD risk factors are considered. These findings suggest an association between early arterial wall alterations and IBD. Such an association should be proven in larger studies that should assess the incidence of CVD in patients with IBD.
GasparyanAYStavropoulos-KalinoglouAMikhailidisDP. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol. 2010;8(4):437–449.
2.
RomanMJShankerBADavisA. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399–2406.
3.
Van DoornumSMcCollGWicksIP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?Arthritis Rheum. 2002;46(4):862–873.
4.
CosnesJGower-RousseauCSeksikP. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–1794.
5.
BernsteinCNWajdaABlanchardJF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6(1):41–45.
6.
HaCMagowanSAccorttNA. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol. 2009;104(6):1445–1451.
7.
HaapamäkiJRoineRPTurunenU. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis. 2011;5(1):41–47.
8.
RungoeCBasitSRantheMF. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2012;62(5):689–694.
9.
CosnesJ. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol. 2004;18(3):481–496.
10.
ChengKSMikhailidisDPHamiltonG. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res. 2002;54(3):528–538.
11.
DaskalopoulouSSDaskalopoulosMEMikhailidisDP. Detection of early atherosclerosis using the ultrasound parameters of the intima-media thickness of the common carotid artery in families with familial combined hyperlipidaemia. Int Angiol. 2005;24(4):395.
12.
TziomalosKAthyrosVGKaragiannisA. The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. Curr Opin Cardiol. 2010;25(4):394–398.
13.
TheocharidouEGossiosTDGioulemeO. Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. Angiology. 2014;65(4):284–293.
14.
DagliNPoyrazogluOKDagliAF. Is inflammatory bowel disease a risk factor for early atherosclerosis?Angiology. 2010;61(2):198–204.
15.
PapaASantoliquidoADaneseS. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22(9):839–846.
16.
van LeuvenSIHezemansRLevelsJH. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res. 2007;48(12):2640–2646.
17.
BroideESchopanAZaretskyM. Intima-media thickness of the common carotid artery is not significantly higher in Crohn's disease patients compared to healthy population. Dig Dis Sci. 2011;56(1):197–202.
18.
KayahanHSariICulluN. Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig Dis Sci. 2012;57(8):2137–2143.
19.
MaharshakNArbelYBornsteinNM. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007;102(5):1050–1055.
20.
SandbornWJFeaganBGHanauerSB. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122(2):512–530.
21.
D'HaensGSandbornWJFeaganBG. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786.
22.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation2002;106(25):3143–3421.
23.
ManciaGDe BackerGDominiczakA. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.
24.
AthyrosVGKakafikaAIKaragiannisAMikhailidisDP. Do we need to consider inflammatory markers when we treat atherosclerotic disease?Atherosclerosis. 2008;200(1):1–12.
25.
LibbyPRidkerPMMaseriA. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143.
26.
TomsTEPanoulasVFDouglasKM. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?Angiology. 2011;62(2):167–175.
27.
RipollesPBNazihHBourreilleA. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55(7):980–988.
28.
PrincipiMMastrolonardoMScicchitanoP. Endothelial function and cardiovascular risk in active inflammatory bowel diseases [published online March 6, 2013]. J Crohns Colitis. 2013.
van derHFDijkstraAWeersmaRK. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2009;15(8):1199–1207.
31.
van derHFDijkstraAAlbersnagelFA. Active and passive smoking behaviour and cessation plans of patients with Crohn's disease and ulcerative colitis. J Crohns Colitis. 2010;4(2):125–131.
32.
SciricaBMMorrowDA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006;113(17):2128–2134.
